My take on the situation, IMHO. The publication of the Thyroid Study does not surprise anyone who is invested already. The results, with minor side effects and dose adjustments are no big deal. The results that matter are that improvement was seen. Name me any other drug, etc. that has accomplished these results. Why has not the price moved on this release? Well, shorty is still in control, and will manipulate to the last second. Major funds that do not cover this stock, will have some upcoming star address the potential for anatabine and have their experts in biotech analyse this study. If they have anyone competant, they should deduce that the results are far more reaching for many autoimmune diseases. All it will take is one or two major funds to get interested in the potential. I will put my faith in Dr. Ladenson, as he is putting his reputation on the line. To have his work peer reviewed, which means others competent of clinical results, are satisfied with the results. The study being accepted and published speaks volumes. Negative comments need to be substantiated by the poster, with some real facts, not just spins. Have a good day all longs, because the news keeps getting better.
